Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's respiratory syncytial virus (RSV) vaccine.
Hannah Green, Biz Journals
Fri, 05/10/2024 - 8:37am
Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's respiratory syncytial virus (RSV) vaccine.